| Nov 14 |
bioAffinity Technologies GAAP EPS of -$0.16 misses by $0.01, revenue of $2.35M misses by $0.19M
|
| Nov 14 |
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
|
| Nov 4 |
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
|
| Oct 30 |
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
|
| Oct 21 |
WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
|
| Oct 21 |
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
|
| Oct 18 |
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
|
| Oct 18 |
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
|
| Oct 16 |
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
|
| Oct 10 |
bioAffinity Technologies names J. Michael Edwards as CFO
|
